Company Overview and News
New Delhi: India’s biggest aluminium producer Vedanta Ltd may be forced to reduce output if restrictions on coal supplies to the non-power sector drag on for another week, according to its chief executive for metals business in the country.
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
British mining and energy group Vedanta Resources Plc is working with regulators to expedite restarting its copper smelter in the southern Indian state of Tamil Nadu, it said on Wednesday, a day after protests turned violent at the plant.
(Reuters) - Shares of Vedanta Ltd (VDAN.NS) fell to their lowest since July 5, 2017, after at least nine people were killed in the southern state of Tamil Nadu when police fired at violent protesters calling for the closure of a copper smelter run by parent Vedanta Resources Plc (VED.L).
Shares of Vedanta slipped more than 5 percent in the early trade on Wednesday as protests seeking closure of copper smelter run by Vedanta Resources at Thoothukudi turned violent, killing 12 people. The violence is said to have started after the police fired at violent protesters.
NEW DELHI (Reuters) - At least nine people were killed in India’s Tamil Nadu state on Tuesday when police fired at violent protesters calling for the closure of a copper smelter run by Vedanta Resources, authorities said.
NEW DELHI (AP) — Officials say nine protesters were killed when police opened fire on demonstrators demanding the closure of a south Indian copper plant.
NEW DELHI, May 22 (Reuters) - At least nine were killed on Tuesday after police fired at protesters calling for the closure of a Vedanta Resources-controlled copper smelter in southern India, a senior police official told Reuters.
From 4/11/18-5/15/18, Fredrik Arnold dividend "followers" discussed 47 equities and funds in their messages and comments.
New Delhi: Renaissance Steel Pvt Ltd, one of the unsuccessful resolution applicant for Electrosteel Steel Ltd, moved the National Company Law Appellate Tribunal (NCLAT) on Friday seeking a declaration that Tata Steel Ltd, another unsuccessful resolution applicant, was ineligible to participate in the resolution process for the debt ridden steel manufacturer under Section 29A of the Insolvency and Bankruptcy Code (IBC).
The Madras High Court today reserved its order on a PIL seeking quashing of the environmental clearance granted to Vedanta Limited's copper smelter unit in Thoothukudi district in Tamil Nadu. Justices M Sundar and Anita Sumant of the Madurai bench of the high court reserved the order on a plea by Fathima Babu, an environmentalist, seeking to stay the environmental clearance to Vedanta's copper smelter unit (formerly Sterlite Industries Limited) by the central government in 2009, subsequently renewed in 2015 and 2016.
New Delhi: The National Company Law Appellate Tribunal (NCLAT) on Thursday admitted the appeal moved by Renaissance Steel India Pvt Ltd, one of the unsuccessful bidders for Electrosteel Steel India Pvt Ltd, against a 17 April order of the National Company Law Tribunal’s Kolkata bench approving Vedanta Ltd’s Rs5,320 crore resolution plan for the debt-riden Electrosteel.
New Delhi: Vedanta Resources Plc’s Thootukudi copper smelter, one of India’s biggest, will remain shut until at least 6 June, a lawyer petitioning against the plant reopening said on Thursday.
The National Company Law Appellate Tribunal (NCLAT) today admitted the petition of Renaissance Steel challenging Vedanta's bid for debt ridden Electrosteel.
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
16h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
17h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET